- Home
- VRCA vs ALXO Comparison
VRCA vs ALXO Comparison
Compare VRCA & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRCA | ALXO |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.5M | 68.3M |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VRCA | ALXO |
|---|---|---|
| Price | $5.90 | $2.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $17.00 | $3.42 |
| AVG Volume (30 Days) | 116.1K | ★ 872.5K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $372.93 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.41 |
| 52 Week High | $9.82 | $2.66 |
Technical Indicators
Market Signals| Indicator | VRCA | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 48.29 | 48.42 |
| Support Level | $5.22 | $2.01 |
| Resistance Level | $6.44 | $2.27 |
| Average True Range (ATR) | 0.39 | 0.22 |
| MACD | 0.08 | -0.06 |
| Stochastic Oscillator | 63.63 | 8.46 |
Price Performance
Historical ComparisonAbout VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.